Literature DB >> 21576013

Local recurrence of pancreatic cancer after primary surgical intervention: how to deal with this devastating scenario?

Ioannis D Kyriazanos1, Grigorios G Tsoukalos, Georgios Papageorgiou, Kosmas E Verigos, Lazaros Miliadis, Christos N Stoidis.   

Abstract

The dismal prognosis of pancreatic cancer reflects into the increased recurrence rate, even after R0 pancreaticoduodenectomy. Although, conventional radiation-, chemo- or surgical therapy in much selected cases, seem to work out favorably long term, less invasive and non-toxic methods with more immediate results are always preferred, concerning the already aggravated status of this group of patients. We present hereby a comprehensive review of the literature concerning the treatment of recurrent pancreatic cancer based on the case of a patient who 20 months after a pancreaticoduodenectomy developed portal hypertension and symptomatic first degree esophageal, gastric and mesenteric varices, caused by the nearly complete splenic vein obstruction at the portal vein confluence. The varices were revascularized by a percutaneous transhepatic placement of an endovascular stent into the splenic vein, along with a sequent stereotactic body radiation therapy for the local tumor control. Thanks to the accuracy and safety of the present combined treatment, the patient one year later presents control of the disease and its complications. Our paper is the first in the international literature that tries to review all the treatment modalities available (surgical, adjuvant, neoadjuvant and palliative therapy) and their efficacy, concerning the locally recurrent pancreatic cancer; furthermore, we tried to analyze the application of the above mentioned combined therapeutic approach in similar cases, elucidating simultaneously all the questions that arise. The limited existing data in the international literature and the lack of randomized controlled trials make this effort difficult, but the physician should be aware after all of all the available and innovative treatment modalities, before he chooses one. Finally, we would like to emphasize the fact that not only the local control but also the management of the complications are important for a prolonged median survival and a better quality of life after all.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21576013     DOI: 10.1016/j.suronc.2011.04.004

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  11 in total

1.  Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.

Authors:  Yixuan Ma; Sina Sender; Anett Sekora; Weibo Kong; Peter Bauer; Najim Ameziane; Susann Krake; Mandy Radefeldt; Ruslan Al-Ali; Frank Ulrich Weiss; Markus M Lerch; Alisha Parveen; Dietmar Zechner; Christian Junghanss; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2022-04-16       Impact factor: 6.208

2.  Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma.

Authors:  Brian A Boone; Herbert J Zeh; Brady K Mock; Paul J Johnson; Igor Dvorchik; Ken Lee; A James Moser; David L Bartlett; J Wallis Marsh
Journal:  HPB (Oxford)       Date:  2013-04-22       Impact factor: 3.647

3.  Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer.

Authors:  Nergiz Dagoglu; Mark Callery; James Moser; Jennifer Tseng; Tara Kent; Andrea Bullock; Rebecca Miksad; Joseph D Mancias; Anand Mahadevan
Journal:  J Cancer       Date:  2016-01-10       Impact factor: 4.207

4.  Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model.

Authors:  Lars Ivo Partecke; André Käding; Dung Nguyen Trung; Stephan Diedrich; Matthias Sendler; Frank Weiss; Jens-Peter Kühn; Julia Mayerle; Katharina Beyer; Wolfram von Bernstorff; Claus-Dieter Heidecke; Wolfram Keßler
Journal:  Oncotarget       Date:  2017-04-04

5.  Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance.

Authors:  V O Oria; P Bronsert; A R Thomsen; M C Föll; C Zamboglou; Luciana Hannibal; S Behringer; M L Biniossek; C Schreiber; A L Grosu; L Bolm; D Rades; T Keck; M Werner; U F Wellner; O Schilling
Journal:  Transl Oncol       Date:  2018-08-30       Impact factor: 4.243

6.  Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway.

Authors:  Xiaodong Xu; Yan Yu; Ke Zong; Pengwei Lv; Yuantin Gu
Journal:  J Exp Clin Cancer Res       Date:  2019-12-18

7.  Effect of Stent Placement on Survival in Patients with Malignant Portal Vein Stenosis: A Propensity Score-Matched Study.

Authors:  Dong Jae Shim; Jong Woo Kim; Doyoung Kim; Gi-Young Ko; Dong Il Gwon; Ji Hoon Shin; Yun-Jung Yang
Journal:  Korean J Radiol       Date:  2022-01       Impact factor: 3.500

8.  Computed Tomography-Guided Cryoablation of Local Recurrence after Primary Resection of Pancreatic Adenocarcinoma.

Authors:  Claudio Pusceddu; Luca Melis; Barbara Sotgia; Alessandro Fancellu; Giovanni Battista Meloni
Journal:  Clin Pract       Date:  2015-06-23

9.  Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis.

Authors:  Zhou Zhou; Yian Cheng; Yinan Jiang; Shi Liu; Meng Zhang; Jing Liu; Qiu Zhao
Journal:  Int J Biol Sci       Date:  2018-01-12       Impact factor: 6.580

10.  Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.

Authors:  Philip A Sutera; Mark E Bernard; Hong Wang; Dwight E Heron
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.